NDATOPICALGEL
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
CABTREO (clindamycin phosphate/benzoyl peroxide/adapalene) by Bausch + Lomb. Approved for retinoid [epc]. First approved in 2023.
Drug data last refreshed 20h ago
Mechanism of Action
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo
Started Apr 2026
100 enrolled
Acne Vulgaris
Company
Bausch + Lomb
Worked on CABTREO at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.